CNS Drugs

, Volume 19, Issue 3, pp 207–223 | Cite as

Effect of Antiepileptic Drugs on Reproductive Endocrine Function in Individuals with Epilepsy

  • Jouko I. T. IsojärviEmail author
  • Erik Taubøll
  • Andrew G. Herzog
Review Article


It is well known that epilepsy, antiepileptic drugs (AEDs), and the reproductive system have complex interactions. Fertility is lower in both men and women with epilepsy than in the general population. Moreover, reproductive endocrine disorders are more common among patients with epilepsy than among the population in general. These disorders have been attributed both to epilepsy itself and to use of AEDs.

The use of the liver enzyme-inducing AEDs phenobarbital, phenytoin and carbamazepine increases serum sex hormone-binding globulin (SHBG) concentrations in both men and women with epilepsy. Over time, the increase in serum SHBG levels leads to diminished bioactivity of testosterone and estradiol, which may result in diminished potency in men and menstrual disorders in some women, and thus to reduced fertility. Liver enzyme-inducing AEDs also reduce the efficacy of oral contraceptives.

Valproic acid medication may have effects on serum androgen concentrations and it reduces serum follicle stimulating hormone levels in men with epilepsy. However, the clinical significance of valproic acid-related reproductive endocrine changes in men is unknown. On the other hand, in women, use of valproic acid appears to be associated with a frequent occurrence of reproductive endocrine disorders characterised by polycystic changes in the ovaries, high serum testosterone concentrations (hyperandrogenism) and menstrual disorders. These disorders are especially common among women who have gained weight during valproic acid treatment. There are some discrepancies regarding the reported occurrence of reproductive endocrine disorders in women taking valproic acid for epilepsy. However, most studies also including patients receiving valproic acid for other reasons than epilepsy, and studies in different non-epileptic animal models, have shown an association between valproic acid medication and hyperandrogenism and related reproductive endocrine disorders.

From a practical point of view, the length of the menstrual cycles and body weight should be monitored in women with epilepsy after commencement of treatment with valproic acid. A serum testosterone assay is helpful in following the possible biochemical endocrine changes. Ultrasonography of the ovaries (preferably transvaginal) is indicated if clinical assessment and serum testosterone measurement imply that there is a clinically significant valproic acid-related reproductive endocrine problem. That would be the case if the menstrual cycles were irregular or prolonged (usually >35 days) and serum testosterone levels elevated, especially with associated weight gain.

The endocrine effects of the new AEDs have not been widely studied. However, it seems they may offer an alternative if reproductive endocrine problems emerge during treatment with the older AEDs.


Carbamazepine Valproic Acid Lamotrigine Polycystic Ovary Serum Testosterone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work has not been financially supported. The manuscript was written during the years 2001–2 and revised in 2003. Since 2003, Jouko Isojärvi has been an employee of GlaxoSmithKline.


  1. 1.
    Dansky LV, Andermann E, Andermann F. Marriage and fertility in epileptic patients. Epilepsia 1980; 21: 261–71PubMedCrossRefGoogle Scholar
  2. 2.
    Webber MP, Hauser WA, Ottman R, et al. Fertility in persons with epilepsy: 1935–1974. Epilepsia 1986; 27: 746–52PubMedCrossRefGoogle Scholar
  3. 3.
    Schupf N, Ottman R. Likelihood of pregnancy in individuals with idiopathic/cryptogenic epilepsy: social and biological influences. Epilepsia 1994; 35: 750–6PubMedCrossRefGoogle Scholar
  4. 4.
    Schupf N, Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for reduced fertility in marriage. Epilepsia 1996; 37: 833–40PubMedCrossRefGoogle Scholar
  5. 5.
    Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2 052 922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352: 1970–3PubMedCrossRefGoogle Scholar
  6. 6.
    Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch Neurol 1986; 43: 347–50PubMedCrossRefGoogle Scholar
  7. 7.
    Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986; 43: 341–6PubMedCrossRefGoogle Scholar
  8. 8.
    Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988; 29: 612–9PubMedCrossRefGoogle Scholar
  9. 9.
    Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383–8PubMedCrossRefGoogle Scholar
  10. 10.
    Trimble MR, Dana-Haeri J, Oxley J, et al. Some neuroendocrine consequences of seizures. In: Porter RJ, Ward Jr AA, Mattson RH, et al., editors. Advances in epileptology: the XVth Epilepsy International Symposium. New York: Raven Press, 1984:210–8Google Scholar
  11. 11.
    Oppenheimer JH, Fisher LV, Nelson KM, et al. Depression of the serum protein-bound iodine level by diphenylhydantoin. J Clin Endocrinol Metab 1961; 21: 252–62PubMedCrossRefGoogle Scholar
  12. 12.
    Fichsel H, Knöpfle G. Effects of anticonvulsant drugs on thyroid hormones in epileptic children. Epilepsia 1978; 19: 323–36PubMedCrossRefGoogle Scholar
  13. 13.
    Liewendahl K, Majuri H, Helenius T. Thyroid function test in patients on long-term treatment with various anticonvulsant drugs. Clin Endocrinol 1978; 8: 185–91CrossRefGoogle Scholar
  14. 14.
    Rootwelt K, Ganes T, Johannessen SI. Effect of carbamazepine, phenytoin and phenobarbital on serum levels of thyroid hormones and thyrotropin in humans. Scand J Clin Lab Invest 1978; 38: 731–6PubMedCrossRefGoogle Scholar
  15. 15.
    Strandjord RE, Aanderud S, Myking OL, et al. Influence of carbamazepine on serum thyroxine and triiodothyronine in patients with epilepsy. Acta Neurol Scand 1981; 63: 111–21PubMedCrossRefGoogle Scholar
  16. 16.
    Beastall GH, Cowan RA, Gray JMB, et al. Hormone binding globulins and anticonvulsant therapy. Scott Med J 1985; 30: 101–5PubMedGoogle Scholar
  17. 17.
    MacPhee GJ, Larkin JG, Butler E, et al. Circulating hormones and pituitary responsiveness in young epileptic men receiving long-term antiepileptic medication. Epilepsia 1988; 29: 468–75PubMedCrossRefGoogle Scholar
  18. 18.
    Isojärvi JIT, Pakarinen AJ, Myllylä VV. Thyroid function in epileptic patients treated with carbamazepine. Arch Neurol 1989; 46: 1175–8PubMedCrossRefGoogle Scholar
  19. 19.
    Isojärvi JIT. Serum steroid hormones and pituitary function in female epileptic patients during carbamazepine therapy. Epilepsia 1990; 31: 438–45PubMedCrossRefGoogle Scholar
  20. 20.
    Isojärvi JIT, Pakarinen AJ, Ylipalosaari PJ, et al. Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch Neurol 1990; 47: 670–6PubMedCrossRefGoogle Scholar
  21. 21.
    Herzog AG, Levesque L, Drislane F, et al. Phenytoin-induced elevation of serum oestradiol and reproductive dysfunction in men with epilepsy. Epilepsia 1991; 32: 550–3CrossRefGoogle Scholar
  22. 22.
    Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia 1995; 36: 676–81PubMedCrossRefGoogle Scholar
  23. 23.
    Isojärvi JIT, Repo M, Pakarinen AJ, et al. Carbamazepine, phenytoin, sex hormones and sexual function in men with epilepsy. Epilepsia 1995; 36: 366–70PubMedCrossRefGoogle Scholar
  24. 24.
    Isojärvi JIT, Laatikainen TJ, Knip M, et al. Obesity and endorine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579–84PubMedCrossRefGoogle Scholar
  25. 25.
    Murialdo G, Galimberti CA, Magri F, et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 1997; 20: 519–26PubMedGoogle Scholar
  26. 26.
    Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446–51PubMedCrossRefGoogle Scholar
  27. 27.
    Murialdo G, Galimberti CA, Gianelli MV, et al. Effects of valproate, phenobarbital and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998; 21: 52–8PubMedGoogle Scholar
  28. 28.
    Vainionpää LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999; 45: 444–50PubMedCrossRefGoogle Scholar
  29. 29.
    Rättyä J, Turkka J, Pakarinen AJ, et al. Reproductive endocrine effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001; 56: 31–6PubMedCrossRefGoogle Scholar
  30. 30.
    Edwards HE, Burnham WM, Ng MM, et al. Limbic seizures alter reproductive function in the female rat. Epilepsia 1999; 40: 1370–7PubMedCrossRefGoogle Scholar
  31. 31.
    Feeney DM, Gullotta FP, Gilmore W. Hyposexuality produced by temporal lobe epilepsy in the cat. Epilepsia 1998; 39: 140–9PubMedCrossRefGoogle Scholar
  32. 32.
    Sperling MR, Pritchard PB, Engel J, et al. Prolactin in partial epilepsy: an indicator of limbic seizures. Ann Neurol 1986; 20: 716–22PubMedCrossRefGoogle Scholar
  33. 33.
    Herzog AG, Coleman AE, Jacobs AR, et al. Interictal EEG discharges, reproductive hormones and menstrual disorders in epilepsy. Ann Neurol 2003; 54: 625–37PubMedCrossRefGoogle Scholar
  34. 34.
    Herzog AG. A relationship between particular reproductive endocrine disorders and the laterality of epileptiform discharges in women with epilepsy. Neurology 1993; 43:1907–10PubMedCrossRefGoogle Scholar
  35. 35.
    Daniele A, Azzoni A, Bizzi A, et al. Sexual behavior and hemispheric laterality of the focus in patients with temporal lobe epilepsy. Biol Psychiatry 1997; 42: 617–24PubMedCrossRefGoogle Scholar
  36. 36.
    Herzog AG, Coleman AE, Jacobs AR, et al. The relationship of sexual function to the laterality of epileptiform discharges and reproductive hormone levels in women with temporolimbic epilepsy. Epilepsy Behav 2003; 4: 407–13PubMedCrossRefGoogle Scholar
  37. 37.
    Mellanby J, Dwyer J, Hawkins CA, et al. Effect of experimental limbic epilepsy on the estrus cycle and reproductive success in rats. Epilepsia 1993; 34: 220–7PubMedCrossRefGoogle Scholar
  38. 38.
    Quigg M, Kiely JM, Shneker B, et al. Interictal and postictal alterations of pulsatile secretion of luteinizing hormone in temporal lobe epilepsy in men. Ann Neurol 2002; 51: 559–66PubMedCrossRefGoogle Scholar
  39. 39.
    Herzog AG, Schachter SC. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001; 42: 311–5PubMedCrossRefGoogle Scholar
  40. 40.
    Mattson RH, Cramer JA. Epilepsy, sex hormones and antiepileptic drugs. Epilepsia 1985; 26Suppl. 1: 40–51SCrossRefGoogle Scholar
  41. 41.
    Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondary generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145–51PubMedCrossRefGoogle Scholar
  42. 42.
    Christiansen P, Lund M. Sexual potency, testicular function and excretion of sexual hormones in male epileptics. In: Janz D, editor. Advances in epileptology: VIIth Epilepsy International Symposium. Berlin: Publishing Sciences Group, 1975: 190–1Google Scholar
  43. 43.
    Barragry JM, Makin HLJ, Trafford DJH, et al. Effect of anticonvulsants on plasma testosterone and sex hormone binding globulin levels. J Neurol Neurosurg Psychiatry 1978; 41: 913–4PubMedCrossRefGoogle Scholar
  44. 44.
    Dana-Haeri J, Oxley J, Richens A. Reduction of free testosterone by antiepileptic drugs. BMJ 1982; 284: 85–6PubMedCrossRefGoogle Scholar
  45. 45.
    Toone BK, Wheeler M, Nanjee M, et al. Sex hormones, sexual activity and plasma anticonvulsant levels in male epileptics. J Neurol Neurosurg Psychiatry 1983; 46: 824–6PubMedCrossRefGoogle Scholar
  46. 46.
    Rodin E, Subramanian MC, Gilroy J. Investigation of sex hormones in male epileptic patients. Epilepsia 1984; 25: 690–4PubMedCrossRefGoogle Scholar
  47. 47.
    Toone BK, Edeh J, Fenwick P, et al. Hormonal and behavioral changes in male epileptics. In: Porter RJ, Ward Jr AA, Mattson RH, et al., editors. Advances in epileptology. XVth Epilepsy International Symposium. New York: Raven Press, 1984: 283–9Google Scholar
  48. 48.
    Petra P. The plasma sex steroid binding protein (SBP or SHBG): a critical review of recent developments on the structure, molecular biology and function. J Steroid Biochem Mol Biol 1991; 40: 735–73PubMedCrossRefGoogle Scholar
  49. 49.
    Isojärvi JIT, Pakarinen AJ, Myllylä VV. Effects of carbamazepine therapy on serum sex hormone levels in male patients with epilepsy. Epilepsia 1988; 29: 781–6PubMedCrossRefGoogle Scholar
  50. 50.
    Isojärvi JIT, Pakarinen AJ, Myllylä VV. A prospective study of serum sex hormones during carbamazepine therapy. Epilepsy Res 1991; 9: 139–44PubMedCrossRefGoogle Scholar
  51. 51.
    Murialdo G, Galimberti CA, Fonzi S, et al. Sex hormones, gonadotropins and prolactin in male epileptic subjects in remission: role of the epileptic syndrome and of antiepileptic drugs. Neuropsychobiology 1994; 30: 29–36PubMedCrossRefGoogle Scholar
  52. 52.
    Duncan S, Blacklaw J, Beastall GH, et al. Antiepileptic drug therapy and sexual function in men with epilepsy. Epilepsia 1999; 40: 197–204PubMedCrossRefGoogle Scholar
  53. 53.
    Rättyä J, Pakarinen AJ, Knip M, et al. Early hormonal changes during valproate or carbamazepine treatment: a 3 month study. Neurology 2001; 57: 440–4PubMedCrossRefGoogle Scholar
  54. 54.
    Isojärvi JIT, Löfgren E, Juntunen KST, et al. Effect of epilepsy and anti-epileptic drugs on male reproductive health. Neurology 2004; 62(2): 247–53PubMedCrossRefGoogle Scholar
  55. 55.
    Herzog AG, Drislane FW, Schomer DL, et al. Differential effects of antiepileptic drug on sexual function and reproductive hormones in men with epilepsy: interim analysis of a comparison between lamotrigine and enzyme-inducing antiepileptic drugs. Epilepsia 2004; 45(7): 764–8PubMedCrossRefGoogle Scholar
  56. 56.
    Murialdo G, Manni R, De Maria A, et al. Luteinizing hormone pulsatile secretion and pituitary response to gonadotropin releasing hormone and to thyrotropin releasing hormone in male epileptic subjects on chronic phenobarbital treatment. J Endocrinol Invest 1987; 10: 27–31PubMedGoogle Scholar
  57. 57.
    Lühdorf K, Christiansen P, Hansen JM, et al. The influence of phenytoin and carbamazepine on endocrine function: preliminary results. In: Penry JK, editor. Epilepsy: the Eighth International Symposium. New York: Raven Press, 1977: 209–13Google Scholar
  58. 58.
    Isojärvi JIT, Pakarinen AJ, Myllylä VV. Effects of carbamazepine on the hypothalamic pituitary-gonadal axis in male patients with epilepsy: a prospective study. Epilepsia 1989; 30: 446–52PubMedCrossRefGoogle Scholar
  59. 59.
    Isojärvi JIT, Pakarinen AJ, Rautio A, et al. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol 1995; 47: 461–4PubMedCrossRefGoogle Scholar
  60. 60.
    Levesque LA, Herzog AG, Seibel MM. The effect of phenytoin and carbamazepine on serum dehydroepiandrosterone sulfate in men and women who have partial seizures with temporal lobe involvement. J Clin Endocrinol Metab 1986; 63: 243–5PubMedCrossRefGoogle Scholar
  61. 61.
    Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984; 18: 401–10PubMedCrossRefGoogle Scholar
  62. 62.
    Connell JMC, Rapeport WG, Beastall GM, et al. Changes in circulating androgens during short term carbamazepine therapy. Br J Clin Pharmacol 1984; 17: 347–51PubMedCrossRefGoogle Scholar
  63. 63.
    Dana-Haeri J, Oxley J, Richens A. Pituitary responsiveness to gonadotrophin-releasing and thyrotrophin-releasing hormones in epileptic patients receiving carbamazepine or phenytoin. Clin Endocrinol 1984; 20: 163–8CrossRefGoogle Scholar
  64. 64.
    Franceschi M, Perego L, Cavagnini F, et al. Effects of long-term antiepileptic therapy on the hypothalamic-pituitary axis in man. Epilepsia 1984; 25: 46–52PubMedCrossRefGoogle Scholar
  65. 65.
    Isojärvi JIT, Myllylä VV, Pakarinen AJ. Effects of carbamazepine on pituitary responsiveness to luteinizing hormone releasing hormone, thyrotropin releasing hormone and metoclopramide in epileptic patients. Epilepsia 1989; 30: 50–6PubMedCrossRefGoogle Scholar
  66. 66.
    Chen SS, Shen MR, Chen TJ, et al. Effects of antiepileptic drugs on sperm motility of normal controls and epileptic patients with long-term therapy. Epilepsia 1992, 53Google Scholar
  67. 67.
    Taneja N, Kucheria K, Jain S, et al. Effect of phenytoin on semen. Epilepsia 1994; 35(1): 136–40PubMedCrossRefGoogle Scholar
  68. 68.
    Cohn DF, Homonnai Z, Paz GF. The effect of anticonvulsant drugs on the development of male rats and their fertility. J Neurol Neurosurg Psychiatry 1982; 45: 844–6PubMedCrossRefGoogle Scholar
  69. 69.
    Soliman GA, Abla Abd E-M. Effect of antiepileptic drugs carbamazepine and sodium valproate on fertility of male rats. Dtsch Tierärztl Wochenschr 1999; 106: 110–3PubMedGoogle Scholar
  70. 70.
    Kühn-Velten W, Herzog AG, Müller MR. Acute effects of anticonvulsant drugs on gonadotropin-stimulated and precursor-supported androgen production in the rat testis. Eur J Pharmacol 1990; 181: 151–5PubMedCrossRefGoogle Scholar
  71. 71.
    Roste LS, Tauboll E, Haugen TB, et al. Alterations in semen parameters in men with epilepsy treated with valproate or carbamazepine monotherapy. Eur J Neurol 2003; 10: 501–6PubMedCrossRefGoogle Scholar
  72. 72.
    Geisler J, Engelsen BA, Berntzen H, et al. Differential effect of carbamazepine and valproate monotherapy on plasma levels of oestrone sulfate and dehydroepiandrosterone sulfate in male epileptic patients. J Endocrinol 1997; 153: 307–12PubMedCrossRefGoogle Scholar
  73. 73.
    Everitt BJ, Keverne EB. Reproduction. In: Lightman SL, Everitt BJ, editors. Neuroendocrinology. Boston (MA): Blackwell Scientific, 1986: 472–537Google Scholar
  74. 74.
    Mattson RH, Cramer JA. Valproic acid. In: Browne TR, Feld-man RG, editors. Epilepsy: diagnosis and management. Boston (MA): Little, Brown, 1983: 225–33Google Scholar
  75. 75.
    Curtis VL, Oelberg DG, Wheless JW, et al. Infertility secondary to valproate therapy [abstract]. Epilepsia 1992; 33 Suppl. 3: 108SGoogle Scholar
  76. 76.
    Yerby MS, McCoy GB. Male infertility: possible association with valproate exposure. Epilepsia 1999; 40: 520–1PubMedCrossRefGoogle Scholar
  77. 77.
    Walker RM, Smith GS, Barsoum NJ, et al. Preclinical toxicology of the anticonvulsant calcium valproate. Toxicology 1990; 63: 137–55PubMedCrossRefGoogle Scholar
  78. 78.
    Røste LS, Taubøll E, Berner A, et al. Morphological changes in the testis after long-term valproate treatment in male Wistar rats. Seizure 2001; 10: 559–65CrossRefGoogle Scholar
  79. 79.
    Grant SM, Faulds D. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992; 43: 873–88PubMedCrossRefGoogle Scholar
  80. 80.
    Larkin JG, McKee PJW, Forrest G, et al. Lack of enzyme induction with oxcarbazepine (600mg daily) in healthy subjects. Br J Clin Pharmacol 1991; 31: 65–71PubMedCrossRefGoogle Scholar
  81. 81.
    Isojärvi JIT, Pakarinen AJ, Rautio A, et al. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994; 35: 1217–20PubMedCrossRefGoogle Scholar
  82. 82.
    Isojärvi JIT, Airaksinen KEJ, Mustonen JN, et al. Thyroid and myocardial function after replacing carbamazepine by oxcarbazepine. Epilepsia 1995; 36: 810–6PubMedCrossRefGoogle Scholar
  83. 83.
    Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependent enzyme induction by oxcarbazepine. Eur J Clin Pharmacol 1990; 39: 187–8PubMedCrossRefGoogle Scholar
  84. 84.
    Laidlaw J. Catamenial epilepsy. Lancet 1956; II: 1235–7CrossRefGoogle Scholar
  85. 85.
    Victor A, Lundberg PO, Johansson EDB. Induction of sex hormone binding globulin by phenytoin. BMJ 1977; 2: 934–5PubMedCrossRefGoogle Scholar
  86. 86.
    Margraf JW, Dreifuss FE. Amenorrhea following initiation of therapy with valproic acid [abstract]. Neurology 1981; 31(4): 159SGoogle Scholar
  87. 87.
    Svalheim S, Taubøll E, Bjørnenak T, et al. Do women with epilepsy have increased frequency of menstrual disturbances? Seizure 2003; 12: 529–33PubMedCrossRefGoogle Scholar
  88. 88.
    Isojärvi JIT, Taubøll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate treated women. Am J Med 2001; 111: 290–6PubMedCrossRefGoogle Scholar
  89. 89.
    Morrell M, Isojärvi J, Taylor AE, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003; 54: 189–99PubMedCrossRefGoogle Scholar
  90. 90.
    Isojärvi JIT. Weight gain, acne and menstrual disorder in a woman with partial epilepsy. In: Schmidt D, Schacter SC, editors. 110 puzzling cases of epilepsy. London: Martin Dunitz, 2002: 320–2Google Scholar
  91. 91.
    Bauer J, Jarre A, Klingmuller D, et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000; 41: 163–7PubMedCrossRefGoogle Scholar
  92. 92.
    Morrell MJ. Epilepsy in women: the science of why it is special. Neurology 1999; 53Suppl. 1: 42–8SGoogle Scholar
  93. 93.
    Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30: 892–6PubMedCrossRefGoogle Scholar
  94. 94.
    Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981; 29: 377–81Google Scholar
  95. 95.
    Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65–9PubMedCrossRefGoogle Scholar
  96. 96.
    Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans; implication for untoward weight gain. Metabolism 1992; 41: 666–70PubMedCrossRefGoogle Scholar
  97. 97.
    Gidal BE, Anderson GD, Spencer NW, et al. Valproate-associated weight gain: potential relation to energy expenditure and metabolism in patients with epilepsy. J Epilepsy 1996; 9: 234–41CrossRefGoogle Scholar
  98. 98.
    Ponchaut S, Veitch K. Valproate and mitochondria. Biochem Pharmacol 1993; 46: 199–204PubMedCrossRefGoogle Scholar
  99. 99.
    Mikkonen K, Vainionpää LK, Pakarinen AJ, et al. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology 2004; 62(3): 445–50PubMedCrossRefGoogle Scholar
  100. 100.
    Bilo L, Meo R, Valentino R, et al. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 2001; 86: 2950–6PubMedCrossRefGoogle Scholar
  101. 101.
    Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy: a comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002; 249: 835–41PubMedCrossRefGoogle Scholar
  102. 102.
    Morrell MJ, Giudice L, Flynn KL, et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol 2002; 52: 704–11PubMedCrossRefGoogle Scholar
  103. 103.
    Betts T, Yarrow H, Dutton N, et al. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. Seizure 2003; 12: 323–9PubMedCrossRefGoogle Scholar
  104. 104.
    Genton P, Bauer J, Duncan S, et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001; 42: 295–304PubMedCrossRefGoogle Scholar
  105. 105.
    Isojärvi JIT, Tauboll E, Tapanainen JS, et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 2001; 42: 305–10PubMedCrossRefGoogle Scholar
  106. 106.
    Joffe H, Taylor AE, Hall JE. Polycystic ovarian syndrome: relationship to epilepsy and antiepileptic drug therapy. J Clin Endocrinol Metab 2001; 86(7): 2946–9PubMedCrossRefGoogle Scholar
  107. 107.
    Bauer J, Isojärvi JIT, Herzog AG, et al. Evaluation and management of reproductive endocrine abnormalities in women with epilepsy. J Neurol Neurosurg Psychiatry 2002; 73: 121–5PubMedCrossRefGoogle Scholar
  108. 108.
    Giudice LC. Insulin-like growth factors and ovarian follicular development. Endocr Rev 1992; 13: 641–9PubMedGoogle Scholar
  109. 109.
    Conover CA, Phillip DKL, Kanaley JA, et al. Insulin regulation of insulin-like growth factor binding protein-1 in obese and non-obese humans. J Clin Endocrinol Metab 1992; 74: 1355–60PubMedCrossRefGoogle Scholar
  110. 110.
    Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 1993; 39: 1–16CrossRefGoogle Scholar
  111. 111.
    Gregoraszczuk E, Wojtowicz AK, Taubøll E, et al. Valproate-induced alterations in testosterone, estradiol and progesterone secretion from porcine follicular cells isolated from small- and medium-sized ovarian follicles. Seizure 2000; 9: 480–5PubMedCrossRefGoogle Scholar
  112. 112.
    Taubøll E, Wojtowicz AK, Ropstad E, et al. Valproate irreversibly alters steroid secretion patterns from porcine follicular cells in vitro. Reprod Toxicol 2002; 16: 319–25PubMedCrossRefGoogle Scholar
  113. 113.
    Taubøll E, Gregoraszczuk EL, Kolodziej A, et al. Valproate inhibits the conversion of testosterone to estradiol and acts as an apoptotic agent in growing porcine ovarian follicular cells. Epilepsia 2003; 44: 1014–21PubMedCrossRefGoogle Scholar
  114. 114.
    Røste LS, Taubøll E, Isojärvi JIT, et al. Effects of chronic valproate treatment on reproductive endocrine hormones in female and male Wistar rats. Reprod Toxicol 2002; 16: 767–73CrossRefGoogle Scholar
  115. 115.
    Hsueh AJW, Adashi EY, Jones PB, et al. Hormonal regulation of the differentiation of cultured ovarian granulosa cells. Endocr Rev 1984; 5: 76–127PubMedCrossRefGoogle Scholar
  116. 116.
    O’Donovan C, Kusumakar V, Graves GR, et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002; 63: 322–30PubMedCrossRefGoogle Scholar
  117. 117.
    Lockard JS, Burkhead-Potter TM, Phillips NK, et al. Is oxcarbazepine (OCBZ) a contraceptive? Pregnancy rate compared to carbamazepine (CBZ), synthetic CBZ 10–11 epoxide (CBZE), and placebo in monkey. Epilepsia 2000; 41Suppl. 7: 97–8SGoogle Scholar
  118. 118.
    Klosterskov-Jensen P, Saano V, Haring P, et al. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992; 33: 1149–52PubMedCrossRefGoogle Scholar
  119. 119.
    Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783–7PubMedCrossRefGoogle Scholar
  120. 120.
    Devinsky O, Vuong A, Hammer A, et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000; 54: 973–5PubMedCrossRefGoogle Scholar
  121. 121.
    Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172–7PubMedCrossRefGoogle Scholar
  122. 122.
    Røste LS, Taubøll E, Berner A, et al. Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats. Exp Toxicol Pathol 2001; 52: 545–52PubMedCrossRefGoogle Scholar
  123. 123.
    Conway GS, Jacobs HS. Clinical implications of hyperinsulinemia in women. Clin Endocrinol 1993; 39: 623–32CrossRefGoogle Scholar
  124. 124.
    Wild RA. Cardiovascular disease risks, insulin resistance, and androgen excess. Semin Reprod Endocrinol 1994; 12: 38–44CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Jouko I. T. Isojärvi
    • 1
    Email author
  • Erik Taubøll
    • 2
  • Andrew G. Herzog
    • 3
  1. 1.Department of NeurologyUniversity of OuluOuluFinland
  2. 2.Department of NeurologyUniversity of OsloOsloNorway
  3. 3.Harvard Neuroendocrine UnitBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations